John Imig
Concepts (553)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Epoxide Hydrolases | 44 | 2024 | 47 | 10.550 |
Why?
| Hypertension | 66 | 2023 | 537 | 10.190 |
Why?
| Kidney | 62 | 2024 | 672 | 8.270 |
Why?
| Kidney Diseases | 22 | 2021 | 214 | 7.390 |
Why?
| 8,11,14-Eicosatrienoic Acid | 19 | 2021 | 19 | 4.890 |
Why?
| Blood Pressure | 56 | 2021 | 524 | 4.720 |
Why?
| Cytochrome P-450 Enzyme System | 27 | 2020 | 195 | 4.700 |
Why?
| Eicosanoids | 15 | 2022 | 19 | 4.090 |
Why?
| Vasodilation | 26 | 2020 | 96 | 3.930 |
Why?
| Renal Insufficiency, Chronic | 9 | 2024 | 169 | 3.360 |
Why?
| Rats | 91 | 2024 | 3299 | 3.340 |
Why?
| Animals | 144 | 2024 | 13246 | 3.320 |
Why?
| Ureteral Obstruction | 6 | 2024 | 61 | 3.310 |
Why?
| Antihypertensive Agents | 20 | 2023 | 121 | 2.990 |
Why?
| Hydroxyeicosatetraenoic Acids | 15 | 2020 | 19 | 2.730 |
Why?
| Cardiovascular Diseases | 9 | 2023 | 443 | 2.670 |
Why?
| Angiotensin II | 32 | 2019 | 157 | 2.620 |
Why?
| Endothelium, Vascular | 13 | 2016 | 254 | 2.550 |
Why?
| Diabetic Nephropathies | 9 | 2021 | 61 | 2.530 |
Why?
| Arachidonic Acids | 9 | 2019 | 22 | 2.260 |
Why?
| Diabetes Mellitus, Experimental | 8 | 2021 | 128 | 2.220 |
Why?
| Enzyme Inhibitors | 20 | 2021 | 386 | 2.170 |
Why?
| Sodium Chloride, Dietary | 11 | 2023 | 33 | 2.000 |
Why?
| Nephritis | 6 | 2024 | 22 | 1.990 |
Why?
| Obesity | 13 | 2018 | 1108 | 1.950 |
Why?
| PPAR gamma | 4 | 2020 | 73 | 1.790 |
Why?
| Oxidative Stress | 15 | 2024 | 771 | 1.700 |
Why?
| Rats, Sprague-Dawley | 47 | 2018 | 1586 | 1.700 |
Why?
| Epoxy Compounds | 5 | 2021 | 45 | 1.680 |
Why?
| Disease Models, Animal | 24 | 2024 | 1458 | 1.590 |
Why?
| Diabetes Mellitus, Type 2 | 7 | 2021 | 486 | 1.540 |
Why?
| Fibrosis | 10 | 2024 | 180 | 1.540 |
Why?
| Male | 98 | 2024 | 25399 | 1.520 |
Why?
| Inflammation | 14 | 2024 | 604 | 1.510 |
Why?
| Lauric Acids | 5 | 2009 | 9 | 1.460 |
Why?
| Mesenteric Arteries | 9 | 2017 | 45 | 1.430 |
Why?
| Fatty Acids | 3 | 2023 | 145 | 1.430 |
Why?
| Adamantane | 5 | 2009 | 25 | 1.430 |
Why?
| Arterioles | 14 | 2018 | 33 | 1.420 |
Why?
| Renal Circulation | 13 | 2019 | 59 | 1.410 |
Why?
| Kidney Glomerulus | 8 | 2018 | 39 | 1.410 |
Why?
| Blood Glucose | 9 | 2021 | 435 | 1.380 |
Why?
| Vasodilator Agents | 9 | 2018 | 98 | 1.380 |
Why?
| Benzimidazoles | 6 | 2014 | 49 | 1.380 |
Why?
| Mice | 35 | 2024 | 5759 | 1.290 |
Why?
| Sodium Chloride | 6 | 2020 | 58 | 1.280 |
Why?
| Myocardial Infarction | 5 | 2021 | 396 | 1.250 |
Why?
| Rats, Inbred SHR | 11 | 2020 | 35 | 1.140 |
Why?
| Hypertension, Renal | 6 | 2016 | 22 | 1.060 |
Why?
| Acute Kidney Injury | 5 | 2022 | 285 | 1.050 |
Why?
| Myocardium | 5 | 2021 | 438 | 1.010 |
Why?
| Oxadiazoles | 3 | 2014 | 10 | 0.980 |
Why?
| Arachidonic Acid | 12 | 2020 | 34 | 0.970 |
Why?
| Albuminuria | 12 | 2018 | 47 | 0.960 |
Why?
| Benzoates | 8 | 2014 | 22 | 0.950 |
Why?
| Collagen | 5 | 2024 | 207 | 0.880 |
Why?
| Phosphates | 1 | 2022 | 47 | 0.840 |
Why?
| Rats, Transgenic | 16 | 2024 | 20 | 0.830 |
Why?
| Cyclooxygenase 2 | 5 | 2016 | 45 | 0.810 |
Why?
| Dietary Fats | 4 | 2011 | 124 | 0.790 |
Why?
| Mice, Inbred C57BL | 16 | 2024 | 1819 | 0.790 |
Why?
| Bradykinin | 3 | 2015 | 17 | 0.780 |
Why?
| Virus Diseases | 1 | 2022 | 40 | 0.780 |
Why?
| Hydroxyproline | 2 | 2024 | 19 | 0.770 |
Why?
| Rats, Inbred WKY | 8 | 2021 | 27 | 0.770 |
Why?
| Humans | 42 | 2023 | 50208 | 0.760 |
Why?
| Metabolic Diseases | 1 | 2021 | 39 | 0.750 |
Why?
| Vasoconstriction | 12 | 2019 | 55 | 0.750 |
Why?
| Myocardial Reperfusion Injury | 2 | 2018 | 48 | 0.740 |
Why?
| Water-Electrolyte Balance | 1 | 2020 | 20 | 0.720 |
Why?
| Prostaglandin-Endoperoxide Synthases | 5 | 2016 | 26 | 0.720 |
Why?
| Muscle, Smooth, Vascular | 9 | 2021 | 129 | 0.720 |
Why?
| Blood Vessels | 1 | 2020 | 71 | 0.710 |
Why?
| Renin-Angiotensin System | 9 | 2019 | 59 | 0.710 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2018 | 122 | 0.690 |
Why?
| Rats, Zucker | 8 | 2018 | 68 | 0.670 |
Why?
| Kidney Transplantation | 1 | 2021 | 175 | 0.670 |
Why?
| Urea | 7 | 2014 | 77 | 0.670 |
Why?
| Liver Cirrhosis | 2 | 2018 | 219 | 0.660 |
Why?
| Heart Diseases | 1 | 2021 | 211 | 0.660 |
Why?
| Fatty Acids, Omega-3 | 2 | 2016 | 27 | 0.640 |
Why?
| Insulin Resistance | 6 | 2018 | 262 | 0.640 |
Why?
| Nitric Oxide | 5 | 2016 | 254 | 0.630 |
Why?
| Proteinuria | 3 | 2016 | 39 | 0.630 |
Why?
| Isoenzymes | 5 | 2006 | 169 | 0.630 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2018 | 56 | 0.620 |
Why?
| Ventricular Remodeling | 1 | 2018 | 54 | 0.610 |
Why?
| Cyclooxygenase 2 Inhibitors | 2 | 2016 | 19 | 0.610 |
Why?
| Renin | 7 | 2016 | 19 | 0.610 |
Why?
| Drug Discovery | 1 | 2018 | 88 | 0.590 |
Why?
| Membrane Proteins | 3 | 2015 | 353 | 0.580 |
Why?
| Angiotensin II Type 1 Receptor Blockers | 4 | 2018 | 43 | 0.580 |
Why?
| Ventricular Function, Left | 1 | 2018 | 159 | 0.580 |
Why?
| Kidney Failure, Chronic | 2 | 2009 | 200 | 0.560 |
Why?
| Solubility | 5 | 2022 | 71 | 0.550 |
Why?
| Natriuresis | 4 | 2020 | 6 | 0.550 |
Why?
| Superoxides | 2 | 2016 | 46 | 0.550 |
Why?
| Neuroprotective Agents | 2 | 2009 | 103 | 0.550 |
Why?
| Cisplatin | 2 | 2021 | 278 | 0.540 |
Why?
| Microcirculation | 11 | 2016 | 71 | 0.540 |
Why?
| Fatty Acids, Unsaturated | 1 | 2016 | 36 | 0.540 |
Why?
| Arachidonate Lipoxygenases | 1 | 2015 | 1 | 0.530 |
Why?
| Brain Ischemia | 2 | 2009 | 161 | 0.530 |
Why?
| Aminopeptidases | 1 | 2015 | 17 | 0.530 |
Why?
| Sodium | 6 | 2023 | 93 | 0.520 |
Why?
| Metabolome | 1 | 2016 | 89 | 0.520 |
Why?
| Cerebral Arteries | 1 | 2015 | 40 | 0.510 |
Why?
| Macrophages | 7 | 2021 | 363 | 0.510 |
Why?
| Angiotensins | 3 | 2010 | 12 | 0.500 |
Why?
| Signal Transduction | 11 | 2018 | 1622 | 0.500 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 244 | 0.490 |
Why?
| Sodium Channel Blockers | 1 | 2014 | 13 | 0.490 |
Why?
| Cardiomegaly | 3 | 2021 | 36 | 0.490 |
Why?
| Tetrazoles | 5 | 2014 | 40 | 0.490 |
Why?
| Gene Expression | 3 | 2015 | 609 | 0.480 |
Why?
| Protective Agents | 1 | 2014 | 14 | 0.480 |
Why?
| Lipids | 5 | 2023 | 148 | 0.480 |
Why?
| Endothelial Cells | 2 | 2013 | 270 | 0.470 |
Why?
| Hypertension, Renovascular | 4 | 2016 | 14 | 0.460 |
Why?
| Homeostasis | 5 | 2016 | 201 | 0.460 |
Why?
| Rats, Inbred Dahl | 6 | 2021 | 10 | 0.450 |
Why?
| Kidney Tubules, Proximal | 4 | 2013 | 62 | 0.450 |
Why?
| Captopril | 2 | 2016 | 12 | 0.450 |
Why?
| Large-Conductance Calcium-Activated Potassium Channels | 3 | 2013 | 12 | 0.440 |
Why?
| Acetylcholine | 5 | 2016 | 54 | 0.440 |
Why?
| Tumor Necrosis Factor-alpha | 4 | 2010 | 388 | 0.440 |
Why?
| Cyclooxygenase Inhibitors | 3 | 2016 | 39 | 0.430 |
Why?
| Cerebrovascular Circulation | 2 | 2011 | 132 | 0.430 |
Why?
| Enalapril | 3 | 2021 | 15 | 0.430 |
Why?
| Calcium | 5 | 2021 | 400 | 0.420 |
Why?
| Cyclic N-Oxides | 2 | 2009 | 12 | 0.420 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2018 | 74 | 0.410 |
Why?
| Benzenesulfonates | 1 | 2012 | 10 | 0.410 |
Why?
| Heart Failure | 3 | 2024 | 506 | 0.410 |
Why?
| Thiazolidinediones | 1 | 2012 | 82 | 0.410 |
Why?
| Growth Inhibitors | 1 | 2012 | 27 | 0.410 |
Why?
| Immunologic Factors | 1 | 2013 | 114 | 0.410 |
Why?
| Cardiovascular Physiological Phenomena | 1 | 2012 | 11 | 0.400 |
Why?
| Apoptosis | 8 | 2019 | 1112 | 0.400 |
Why?
| Vasoconstrictor Agents | 7 | 2019 | 84 | 0.400 |
Why?
| Hypertension, Malignant | 3 | 2018 | 4 | 0.400 |
Why?
| Vascular Endothelial Growth Factor A | 2 | 2012 | 202 | 0.400 |
Why?
| Breast Neoplasms | 1 | 2021 | 1179 | 0.390 |
Why?
| Sulfones | 3 | 2010 | 24 | 0.390 |
Why?
| Pyridines | 2 | 2012 | 131 | 0.390 |
Why?
| Hypoglycemic Agents | 2 | 2012 | 168 | 0.390 |
Why?
| Dose-Response Relationship, Drug | 10 | 2019 | 1378 | 0.390 |
Why?
| Endoplasmic Reticulum Stress | 4 | 2017 | 43 | 0.380 |
Why?
| Chemokine CCL2 | 7 | 2011 | 71 | 0.380 |
Why?
| NG-Nitroarginine Methyl Ester | 3 | 2016 | 18 | 0.380 |
Why?
| Potassium Channels | 3 | 2012 | 32 | 0.370 |
Why?
| Valine | 1 | 2011 | 58 | 0.370 |
Why?
| Drug Delivery Systems | 2 | 2009 | 146 | 0.370 |
Why?
| Arrhythmias, Cardiac | 3 | 2021 | 93 | 0.360 |
Why?
| Actins | 2 | 2024 | 119 | 0.350 |
Why?
| Receptors, Adrenergic, alpha-2 | 1 | 2009 | 8 | 0.350 |
Why?
| Simvastatin | 1 | 2009 | 29 | 0.340 |
Why?
| Mice, Knockout | 10 | 2021 | 846 | 0.340 |
Why?
| Oleic Acids | 1 | 2009 | 8 | 0.340 |
Why?
| Oxidoreductases | 2 | 2008 | 60 | 0.330 |
Why?
| Potassium, Dietary | 1 | 2009 | 2 | 0.330 |
Why?
| PPAR alpha | 2 | 2006 | 58 | 0.320 |
Why?
| Thrombosis | 2 | 2022 | 248 | 0.320 |
Why?
| Diabetes Mellitus, Type 1 | 1 | 2011 | 201 | 0.320 |
Why?
| Gene Deletion | 2 | 2009 | 270 | 0.320 |
Why?
| Cytochrome P-450 CYP1A1 | 5 | 2018 | 26 | 0.320 |
Why?
| Hypnotics and Sedatives | 1 | 2009 | 75 | 0.320 |
Why?
| Receptor, Angiotensin, Type 1 | 4 | 2005 | 57 | 0.320 |
Why?
| Sulfonamides | 2 | 2022 | 128 | 0.310 |
Why?
| Carrier Proteins | 2 | 2013 | 306 | 0.310 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2013 | 595 | 0.300 |
Why?
| Potassium Channels, Calcium-Activated | 2 | 2007 | 5 | 0.300 |
Why?
| Receptors, CCR2 | 1 | 2007 | 14 | 0.300 |
Why?
| Body Weight | 4 | 2014 | 512 | 0.300 |
Why?
| Gene Expression Regulation | 3 | 2016 | 979 | 0.300 |
Why?
| Hemodynamics | 3 | 2015 | 263 | 0.290 |
Why?
| Receptors, Prostaglandin E | 2 | 2007 | 2 | 0.290 |
Why?
| Nitric Oxide Synthase | 4 | 2016 | 75 | 0.290 |
Why?
| Calcium Channels | 2 | 2005 | 46 | 0.290 |
Why?
| Drug Evaluation, Preclinical | 4 | 2018 | 143 | 0.280 |
Why?
| Disease Progression | 5 | 2015 | 831 | 0.280 |
Why?
| Phosphoprotein Phosphatases | 1 | 2006 | 17 | 0.280 |
Why?
| Receptors, Cytoplasmic and Nuclear | 2 | 2019 | 64 | 0.280 |
Why?
| Glucose Tolerance Test | 2 | 2018 | 56 | 0.270 |
Why?
| Immunoglobulin G | 2 | 2007 | 186 | 0.270 |
Why?
| Cholesterol | 3 | 2014 | 147 | 0.270 |
Why?
| Hypolipidemic Agents | 1 | 2006 | 27 | 0.270 |
Why?
| Fenofibrate | 1 | 2006 | 17 | 0.270 |
Why?
| Heme Oxygenase-1 | 2 | 2019 | 19 | 0.260 |
Why?
| Purinergic P2 Receptor Agonists | 2 | 2005 | 4 | 0.260 |
Why?
| Cerebral Infarction | 1 | 2005 | 39 | 0.260 |
Why?
| NF-kappa B | 5 | 2013 | 315 | 0.260 |
Why?
| RNA, Messenger | 6 | 2007 | 1108 | 0.260 |
Why?
| Insulin | 5 | 2014 | 456 | 0.250 |
Why?
| Hyperglycemia | 2 | 2017 | 78 | 0.250 |
Why?
| Chloride Channels | 2 | 2021 | 26 | 0.250 |
Why?
| Adenosine Triphosphate | 3 | 2005 | 233 | 0.250 |
Why?
| Lactones | 1 | 2004 | 26 | 0.240 |
Why?
| Islets of Langerhans | 2 | 2017 | 24 | 0.240 |
Why?
| Nephrotic Syndrome | 1 | 2024 | 18 | 0.240 |
Why?
| Kidney Cortex | 5 | 2007 | 22 | 0.240 |
Why?
| Heart | 2 | 2019 | 331 | 0.240 |
Why?
| Administration, Oral | 5 | 2017 | 434 | 0.240 |
Why?
| Cell Line, Tumor | 3 | 2021 | 1416 | 0.230 |
Why?
| Biological Factors | 1 | 2004 | 10 | 0.230 |
Why?
| Fibroblasts | 3 | 2021 | 351 | 0.230 |
Why?
| Osteonectin | 3 | 2008 | 10 | 0.230 |
Why?
| Hypertrophy | 1 | 2024 | 50 | 0.230 |
Why?
| Rats, Inbred Strains | 3 | 2015 | 194 | 0.230 |
Why?
| Time Factors | 8 | 2016 | 2922 | 0.230 |
Why?
| Dinoprostone | 2 | 2007 | 53 | 0.230 |
Why?
| 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2003 | 2 | 0.230 |
Why?
| Phenylurea Compounds | 2 | 2014 | 15 | 0.230 |
Why?
| Stroke Volume | 1 | 2024 | 129 | 0.230 |
Why?
| Receptor, Bradykinin B2 | 1 | 2003 | 7 | 0.230 |
Why?
| Thiobarbituric Acid Reactive Substances | 3 | 2013 | 9 | 0.220 |
Why?
| Osteopontin | 1 | 2022 | 14 | 0.210 |
Why?
| Doxorubicin | 1 | 2024 | 239 | 0.210 |
Why?
| Alprostadil | 1 | 2002 | 10 | 0.210 |
Why?
| Minerals | 1 | 2022 | 30 | 0.210 |
Why?
| Diet, High-Fat | 3 | 2021 | 220 | 0.210 |
Why?
| Sex Characteristics | 1 | 2024 | 191 | 0.210 |
Why?
| Steroid 16-alpha-Hydroxylase | 4 | 2016 | 10 | 0.210 |
Why?
| Carbazoles | 1 | 2022 | 16 | 0.200 |
Why?
| Amides | 4 | 2018 | 39 | 0.200 |
Why?
| Substance P | 1 | 2021 | 27 | 0.200 |
Why?
| Aryl Hydrocarbon Hydroxylases | 4 | 2016 | 74 | 0.200 |
Why?
| Adaptation, Physiological | 1 | 2002 | 91 | 0.190 |
Why?
| Tachycardia, Ventricular | 1 | 2021 | 45 | 0.190 |
Why?
| Inflammation Mediators | 3 | 2013 | 113 | 0.190 |
Why?
| Desoxycorticosterone | 3 | 2009 | 6 | 0.190 |
Why?
| Isoprostanes | 1 | 2020 | 2 | 0.190 |
Why?
| I-kappa B Kinase | 2 | 2011 | 20 | 0.190 |
Why?
| Vascular Stiffness | 1 | 2021 | 18 | 0.190 |
Why?
| Paracrine Communication | 1 | 2020 | 12 | 0.190 |
Why?
| Peptides | 2 | 2015 | 223 | 0.180 |
Why?
| Tumor Burden | 1 | 2021 | 131 | 0.180 |
Why?
| Mice, Nude | 1 | 2021 | 254 | 0.180 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2021 | 212 | 0.180 |
Why?
| Down-Regulation | 3 | 2018 | 349 | 0.180 |
Why?
| Water-Electrolyte Imbalance | 1 | 2020 | 15 | 0.180 |
Why?
| Metabolic Networks and Pathways | 1 | 2020 | 89 | 0.180 |
Why?
| Potassium | 1 | 2020 | 56 | 0.180 |
Why?
| Muscle Contraction | 1 | 2021 | 106 | 0.180 |
Why?
| Risk | 1 | 2021 | 324 | 0.180 |
Why?
| Renal Dialysis | 1 | 2021 | 170 | 0.170 |
Why?
| Receptors, Neurokinin-1 | 1 | 2019 | 9 | 0.170 |
Why?
| Forecasting | 1 | 2020 | 150 | 0.170 |
Why?
| Chenodeoxycholic Acid | 1 | 2019 | 7 | 0.170 |
Why?
| Endothelin-1 | 5 | 2008 | 31 | 0.170 |
Why?
| Golgi Apparatus | 1 | 2021 | 114 | 0.170 |
Why?
| Mast Cells | 1 | 2019 | 52 | 0.170 |
Why?
| Nitric Oxide Synthase Type III | 2 | 2012 | 78 | 0.170 |
Why?
| Cardiotonic Agents | 2 | 2012 | 82 | 0.160 |
Why?
| KATP Channels | 1 | 2018 | 6 | 0.160 |
Why?
| 3' Untranslated Regions | 1 | 2018 | 52 | 0.160 |
Why?
| Drug Therapy, Combination | 4 | 2018 | 381 | 0.160 |
Why?
| Proteolysis | 1 | 2018 | 95 | 0.150 |
Why?
| Antioxidants | 3 | 2009 | 241 | 0.150 |
Why?
| Protein Phosphatase 2 | 2 | 2008 | 5 | 0.150 |
Why?
| Weight Gain | 3 | 2010 | 239 | 0.150 |
Why?
| Receptor, Cannabinoid, CB1 | 2 | 2009 | 125 | 0.150 |
Why?
| Muscle Cells | 2 | 2008 | 22 | 0.150 |
Why?
| Female | 11 | 2024 | 26635 | 0.150 |
Why?
| Epithelial Sodium Channels | 2 | 2013 | 8 | 0.150 |
Why?
| Blood Urea Nitrogen | 2 | 2016 | 41 | 0.140 |
Why?
| Fatty Liver | 1 | 2018 | 127 | 0.140 |
Why?
| Carcinoma | 2 | 2008 | 139 | 0.140 |
Why?
| Vascular Resistance | 2 | 2006 | 57 | 0.140 |
Why?
| Species Specificity | 2 | 2016 | 192 | 0.140 |
Why?
| Indomethacin | 1 | 2016 | 38 | 0.130 |
Why?
| Stereoisomerism | 1 | 2016 | 103 | 0.130 |
Why?
| Podocytes | 2 | 2017 | 19 | 0.130 |
Why?
| Cyclosporine | 1 | 2016 | 65 | 0.130 |
Why?
| Renal Artery | 1 | 2016 | 33 | 0.130 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2016 | 48 | 0.130 |
Why?
| Receptor, Adenosine A2B | 1 | 2015 | 3 | 0.130 |
Why?
| Clinical Trials as Topic | 1 | 2018 | 466 | 0.130 |
Why?
| Whole-Body Irradiation | 1 | 2016 | 131 | 0.130 |
Why?
| Phosphorylation | 3 | 2013 | 534 | 0.130 |
Why?
| Ion Channel Gating | 2 | 2006 | 39 | 0.130 |
Why?
| Radiation-Protective Agents | 1 | 2016 | 74 | 0.130 |
Why?
| Radiation Injuries, Experimental | 1 | 2016 | 81 | 0.130 |
Why?
| Epigenesis, Genetic | 1 | 2018 | 378 | 0.130 |
Why?
| Cytokines | 3 | 2021 | 613 | 0.130 |
Why?
| Nephrosclerosis | 1 | 2014 | 4 | 0.120 |
Why?
| Glucose | 2 | 2021 | 338 | 0.120 |
Why?
| Immunosuppressive Agents | 1 | 2016 | 222 | 0.120 |
Why?
| Receptors, Purinergic P2 | 2 | 2005 | 39 | 0.120 |
Why?
| Calcium Signaling | 2 | 2005 | 56 | 0.120 |
Why?
| Hypertrophy, Left Ventricular | 1 | 2014 | 40 | 0.120 |
Why?
| Glucose Intolerance | 1 | 2014 | 27 | 0.120 |
Why?
| Coronary Vessels | 2 | 2014 | 157 | 0.120 |
Why?
| Fructose | 1 | 2013 | 22 | 0.120 |
Why?
| Caspase Inhibitors | 1 | 2013 | 16 | 0.110 |
Why?
| Myocytes, Smooth Muscle | 3 | 2021 | 86 | 0.110 |
Why?
| Gene Expression Regulation, Enzymologic | 2 | 2005 | 180 | 0.110 |
Why?
| Ovarian Neoplasms | 2 | 2008 | 447 | 0.110 |
Why?
| Eye Diseases | 1 | 2013 | 38 | 0.110 |
Why?
| Triglycerides | 1 | 2014 | 155 | 0.110 |
Why?
| Cell Survival | 2 | 2013 | 602 | 0.110 |
Why?
| Receptor, Endothelin A | 2 | 2019 | 8 | 0.110 |
Why?
| Cross-Linking Reagents | 1 | 2013 | 43 | 0.110 |
Why?
| Retina | 1 | 2013 | 65 | 0.110 |
Why?
| Inflammasomes | 1 | 2013 | 59 | 0.110 |
Why?
| Rats, Wistar | 2 | 2013 | 222 | 0.110 |
Why?
| Human Umbilical Vein Endothelial Cells | 1 | 2013 | 90 | 0.110 |
Why?
| Creatinine | 1 | 2013 | 141 | 0.110 |
Why?
| Nephrectomy | 3 | 2019 | 83 | 0.110 |
Why?
| Indoles | 4 | 2018 | 278 | 0.110 |
Why?
| Cyclic AMP | 2 | 2015 | 91 | 0.110 |
Why?
| Superoxide Dismutase | 1 | 2013 | 114 | 0.110 |
Why?
| Spin Labels | 2 | 2009 | 5 | 0.110 |
Why?
| Angiotensin I | 3 | 2016 | 14 | 0.100 |
Why?
| Interleukin-6 | 3 | 2015 | 265 | 0.100 |
Why?
| HEK293 Cells | 1 | 2013 | 224 | 0.100 |
Why?
| HeLa Cells | 1 | 2013 | 260 | 0.100 |
Why?
| Small Molecule Libraries | 1 | 2013 | 68 | 0.100 |
Why?
| Structure-Activity Relationship | 2 | 2017 | 401 | 0.100 |
Why?
| Niacinamide | 1 | 2012 | 22 | 0.100 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 129 | 0.100 |
Why?
| Receptors, Angiotensin | 2 | 2002 | 13 | 0.100 |
Why?
| Blotting, Western | 4 | 2010 | 601 | 0.100 |
Why?
| Immunity, Innate | 1 | 2013 | 105 | 0.100 |
Why?
| Syndrome | 1 | 2012 | 238 | 0.100 |
Why?
| Anti-Inflammatory Agents | 1 | 2013 | 160 | 0.100 |
Why?
| Platelet Aggregation | 1 | 2012 | 71 | 0.100 |
Why?
| Transcription Factor RelA | 1 | 2011 | 30 | 0.100 |
Why?
| Neovascularization, Physiologic | 1 | 2012 | 68 | 0.100 |
Why?
| Catalase | 1 | 2011 | 68 | 0.100 |
Why?
| Angiotensin II Type 2 Receptor Blockers | 1 | 2011 | 7 | 0.100 |
Why?
| Cell Adhesion Molecules | 1 | 2011 | 89 | 0.090 |
Why?
| Receptors, Purinergic P2X | 3 | 2005 | 6 | 0.090 |
Why?
| Models, Biological | 2 | 2021 | 723 | 0.090 |
Why?
| Hydralazine | 2 | 2014 | 4 | 0.090 |
Why?
| Reserpine | 2 | 2014 | 13 | 0.090 |
Why?
| Hydrochlorothiazide | 2 | 2014 | 7 | 0.090 |
Why?
| Cells, Cultured | 3 | 2011 | 1581 | 0.090 |
Why?
| Pyrrolidines | 3 | 2005 | 83 | 0.090 |
Why?
| Kidney Function Tests | 1 | 2010 | 49 | 0.090 |
Why?
| Nitrites | 1 | 2010 | 31 | 0.090 |
Why?
| Multiple Organ Failure | 1 | 2010 | 47 | 0.090 |
Why?
| Biphenyl Compounds | 3 | 2005 | 31 | 0.090 |
Why?
| Epithelial Cells | 1 | 2011 | 207 | 0.090 |
Why?
| Dietary Supplements | 1 | 2013 | 434 | 0.090 |
Why?
| Molecular Targeted Therapy | 1 | 2010 | 121 | 0.090 |
Why?
| Receptors, Tumor Necrosis Factor | 2 | 2007 | 35 | 0.090 |
Why?
| Cardiovascular Agents | 1 | 2009 | 54 | 0.080 |
Why?
| TRPV Cation Channels | 1 | 2009 | 8 | 0.080 |
Why?
| Microvessels | 1 | 2009 | 31 | 0.080 |
Why?
| Receptors, Cannabinoid | 1 | 2009 | 19 | 0.080 |
Why?
| Matrix Metalloproteinase 2 | 2 | 2007 | 57 | 0.080 |
Why?
| Mice, Obese | 1 | 2009 | 21 | 0.080 |
Why?
| Endothelins | 2 | 2005 | 17 | 0.080 |
Why?
| Protein Structure, Tertiary | 1 | 2009 | 253 | 0.080 |
Why?
| Aorta | 2 | 2007 | 162 | 0.080 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 138 | 0.080 |
Why?
| Receptors, CCR1 | 1 | 2007 | 10 | 0.080 |
Why?
| Cattle | 3 | 2014 | 219 | 0.080 |
Why?
| Ascitic Fluid | 1 | 2007 | 12 | 0.080 |
Why?
| Capillaries | 2 | 2005 | 50 | 0.080 |
Why?
| Receptor, Cannabinoid, CB2 | 1 | 2008 | 58 | 0.070 |
Why?
| Cell Separation | 2 | 2005 | 90 | 0.070 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2007 | 63 | 0.070 |
Why?
| Glomerular Filtration Rate | 3 | 2013 | 111 | 0.070 |
Why?
| Oxygenases | 2 | 2007 | 14 | 0.070 |
Why?
| Adult | 1 | 2023 | 13324 | 0.070 |
Why?
| Norepinephrine | 2 | 2010 | 113 | 0.070 |
Why?
| Charybdotoxin | 1 | 2006 | 1 | 0.070 |
Why?
| Okadaic Acid | 1 | 2006 | 8 | 0.070 |
Why?
| Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2006 | 6 | 0.070 |
Why?
| Angiotensin Receptor Antagonists | 2 | 2004 | 19 | 0.070 |
Why?
| Peritoneal Neoplasms | 1 | 2007 | 59 | 0.070 |
Why?
| Tetraethylammonium Compounds | 1 | 2006 | 3 | 0.070 |
Why?
| Triazoles | 1 | 2007 | 109 | 0.070 |
Why?
| Leptin | 1 | 2007 | 140 | 0.070 |
Why?
| Arteries | 1 | 2007 | 92 | 0.070 |
Why?
| NADPH-Ferrihemoprotein Reductase | 1 | 2006 | 14 | 0.070 |
Why?
| Receptor, Endothelin B | 1 | 2005 | 2 | 0.070 |
Why?
| Penile Erection | 1 | 2006 | 22 | 0.070 |
Why?
| Sodium-Potassium-Exchanging ATPase | 1 | 2006 | 61 | 0.070 |
Why?
| Immunoblotting | 1 | 2006 | 117 | 0.070 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2005 | 89 | 0.060 |
Why?
| Cell Count | 1 | 2005 | 149 | 0.060 |
Why?
| Transcriptional Activation | 1 | 2005 | 121 | 0.060 |
Why?
| Penis | 1 | 2006 | 79 | 0.060 |
Why?
| Juxtaglomerular Apparatus | 1 | 2004 | 2 | 0.060 |
Why?
| Nephrons | 1 | 2004 | 6 | 0.060 |
Why?
| Molecular Structure | 1 | 2006 | 296 | 0.060 |
Why?
| Peroxisome Proliferator-Activated Receptors | 2 | 2014 | 14 | 0.060 |
Why?
| Thromboxane B2 | 1 | 2004 | 8 | 0.060 |
Why?
| Chemokines | 1 | 2004 | 78 | 0.060 |
Why?
| Spectrometry, Fluorescence | 1 | 2004 | 46 | 0.060 |
Why?
| Linoleic Acid | 1 | 2004 | 14 | 0.060 |
Why?
| Calcium Channels, L-Type | 1 | 2004 | 67 | 0.060 |
Why?
| Suramin | 1 | 2003 | 12 | 0.060 |
Why?
| Lipoxygenase | 1 | 2003 | 1 | 0.060 |
Why?
| Antibiotics, Antineoplastic | 1 | 2024 | 81 | 0.060 |
Why?
| Dogs | 1 | 2004 | 185 | 0.060 |
Why?
| Survival Rate | 2 | 2018 | 901 | 0.060 |
Why?
| Cell Death | 2 | 2014 | 182 | 0.060 |
Why?
| Prostaglandins E, Synthetic | 1 | 2002 | 1 | 0.050 |
Why?
| Receptors, Prostaglandin E, EP2 Subtype | 1 | 2002 | 1 | 0.050 |
Why?
| Gene Expression Profiling | 1 | 2007 | 1037 | 0.050 |
Why?
| Heart Rate | 1 | 2004 | 298 | 0.050 |
Why?
| Diabetes Mellitus | 1 | 2006 | 286 | 0.050 |
Why?
| Chemoprevention | 1 | 2022 | 15 | 0.050 |
Why?
| Endosomes | 1 | 2002 | 33 | 0.050 |
Why?
| Up-Regulation | 1 | 2003 | 453 | 0.050 |
Why?
| Biological Transport | 2 | 2013 | 172 | 0.050 |
Why?
| Receptors, Leptin | 1 | 2021 | 44 | 0.050 |
Why?
| Promoter Regions, Genetic | 2 | 2016 | 475 | 0.050 |
Why?
| Risk Factors | 1 | 2009 | 3629 | 0.050 |
Why?
| Regional Blood Flow | 2 | 2011 | 108 | 0.050 |
Why?
| Peptide Fragments | 2 | 2016 | 213 | 0.050 |
Why?
| Sodium, Dietary | 1 | 2021 | 26 | 0.050 |
Why?
| Treatment Outcome | 1 | 2011 | 5155 | 0.050 |
Why?
| Rats, Inbred F344 | 2 | 2014 | 196 | 0.040 |
Why?
| Random Allocation | 2 | 2013 | 282 | 0.040 |
Why?
| Arterio-Arterial Fistula | 1 | 2019 | 2 | 0.040 |
Why?
| 3T3 Cells | 1 | 2019 | 56 | 0.040 |
Why?
| Aging | 1 | 2004 | 688 | 0.040 |
Why?
| Pinacidil | 1 | 2018 | 1 | 0.040 |
Why?
| Phenotype | 1 | 2021 | 733 | 0.040 |
Why?
| Pulmonary Artery | 1 | 2019 | 145 | 0.040 |
Why?
| Fatty Acids, Monounsaturated | 1 | 2017 | 9 | 0.040 |
Why?
| Base Sequence | 2 | 2010 | 644 | 0.040 |
Why?
| Mice, Mutant Strains | 2 | 2007 | 71 | 0.040 |
Why?
| Dinoprost | 2 | 2007 | 8 | 0.040 |
Why?
| Mice, Transgenic | 2 | 2010 | 550 | 0.040 |
Why?
| Rats, Inbred BN | 1 | 2016 | 17 | 0.030 |
Why?
| Albumins | 1 | 2016 | 31 | 0.030 |
Why?
| Hydrogen Peroxide | 2 | 2007 | 115 | 0.030 |
Why?
| Fas Ligand Protein | 1 | 2016 | 17 | 0.030 |
Why?
| Cytoprotection | 1 | 2016 | 35 | 0.030 |
Why?
| Autophagy | 1 | 2017 | 169 | 0.030 |
Why?
| Adenosine A2 Receptor Agonists | 1 | 2015 | 5 | 0.030 |
Why?
| Glycogen Synthase Kinase 3 | 1 | 2015 | 20 | 0.030 |
Why?
| Aminopyridines | 1 | 2015 | 15 | 0.030 |
Why?
| Telemetry | 1 | 2015 | 32 | 0.030 |
Why?
| Blood Pressure Monitoring, Ambulatory | 1 | 2015 | 36 | 0.030 |
Why?
| Oxamic Acid | 1 | 2014 | 1 | 0.030 |
Why?
| Proto-Oncogene Proteins c-akt | 1 | 2015 | 157 | 0.030 |
Why?
| Glomerular Basement Membrane | 1 | 2014 | 10 | 0.030 |
Why?
| Chemistry Techniques, Synthetic | 1 | 2014 | 20 | 0.030 |
Why?
| Pressure | 2 | 2006 | 106 | 0.030 |
Why?
| Orchiectomy | 1 | 2014 | 41 | 0.030 |
Why?
| Molecular Mimicry | 1 | 2014 | 38 | 0.030 |
Why?
| Sex Factors | 2 | 2008 | 697 | 0.030 |
Why?
| Necrosis | 1 | 2014 | 178 | 0.030 |
Why?
| Sweetening Agents | 1 | 2013 | 22 | 0.030 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2013 | 49 | 0.030 |
Why?
| Cell Proliferation | 2 | 2008 | 1013 | 0.030 |
Why?
| Epithelial Sodium Channel Blockers | 1 | 2013 | 3 | 0.030 |
Why?
| Hydrogen-Ion Concentration | 1 | 2013 | 176 | 0.030 |
Why?
| Peptidyl-Dipeptidase A | 1 | 2013 | 27 | 0.030 |
Why?
| Lipid Peroxidation | 1 | 2013 | 100 | 0.030 |
Why?
| Mice, Inbred Strains | 1 | 2013 | 161 | 0.030 |
Why?
| Cell Cycle Proteins | 1 | 2013 | 166 | 0.030 |
Why?
| Muscle Relaxation | 1 | 2012 | 15 | 0.030 |
Why?
| Isometric Contraction | 1 | 2012 | 21 | 0.030 |
Why?
| Coronary Circulation | 1 | 2012 | 59 | 0.020 |
Why?
| Patch-Clamp Techniques | 1 | 2012 | 124 | 0.020 |
Why?
| Membrane Potentials | 1 | 2012 | 117 | 0.020 |
Why?
| Amitrole | 1 | 2011 | 1 | 0.020 |
Why?
| Drug Contamination | 1 | 2011 | 4 | 0.020 |
Why?
| Losartan | 1 | 2011 | 27 | 0.020 |
Why?
| Insulin Receptor Substrate Proteins | 1 | 2011 | 11 | 0.020 |
Why?
| Combined Modality Therapy | 1 | 2013 | 636 | 0.020 |
Why?
| Amidines | 1 | 2011 | 8 | 0.020 |
Why?
| Obesity, Abdominal | 1 | 2011 | 14 | 0.020 |
Why?
| Renal Plasma Flow | 1 | 2011 | 4 | 0.020 |
Why?
| Pancreas | 1 | 2011 | 70 | 0.020 |
Why?
| Mass Spectrometry | 1 | 2012 | 301 | 0.020 |
Why?
| In Situ Hybridization | 1 | 2010 | 65 | 0.020 |
Why?
| DNA Primers | 1 | 2010 | 207 | 0.020 |
Why?
| Mutation | 1 | 2015 | 1294 | 0.020 |
Why?
| Androgens | 1 | 2009 | 69 | 0.020 |
Why?
| U937 Cells | 1 | 2008 | 14 | 0.020 |
Why?
| Chemotaxis, Leukocyte | 1 | 2008 | 13 | 0.020 |
Why?
| Luteinizing Hormone | 1 | 2008 | 49 | 0.020 |
Why?
| HL-60 Cells | 1 | 2008 | 18 | 0.020 |
Why?
| Epithelium | 1 | 2008 | 65 | 0.020 |
Why?
| Follicle Stimulating Hormone | 1 | 2008 | 43 | 0.020 |
Why?
| Cricetulus | 1 | 2008 | 108 | 0.020 |
Why?
| Coculture Techniques | 1 | 2008 | 146 | 0.020 |
Why?
| Estrogen Replacement Therapy | 1 | 2008 | 41 | 0.020 |
Why?
| CHO Cells | 1 | 2008 | 121 | 0.020 |
Why?
| Organ Specificity | 1 | 2008 | 108 | 0.020 |
Why?
| Cricetinae | 1 | 2008 | 212 | 0.020 |
Why?
| Ovary | 1 | 2008 | 115 | 0.020 |
Why?
| Mineralocorticoids | 1 | 2007 | 2 | 0.020 |
Why?
| Testosterone | 1 | 2008 | 140 | 0.020 |
Why?
| Tissue Inhibitor of Metalloproteinases | 1 | 2007 | 11 | 0.020 |
Why?
| Receptors, Prostaglandin E, EP1 Subtype | 1 | 2007 | 1 | 0.020 |
Why?
| Glomerular Mesangium | 1 | 2007 | 7 | 0.020 |
Why?
| Integrins | 1 | 2007 | 31 | 0.020 |
Why?
| Neoplasm Invasiveness | 1 | 2008 | 266 | 0.020 |
Why?
| Animals, Genetically Modified | 1 | 2007 | 49 | 0.020 |
Why?
| Cobalt | 1 | 2007 | 16 | 0.020 |
Why?
| Glomerulosclerosis, Focal Segmental | 1 | 2007 | 13 | 0.020 |
Why?
| Protein Kinase C | 1 | 2007 | 71 | 0.020 |
Why?
| Metalloendopeptidases | 1 | 2007 | 69 | 0.020 |
Why?
| Heterozygote | 1 | 2007 | 81 | 0.020 |
Why?
| Cyclic GMP | 1 | 2007 | 20 | 0.020 |
Why?
| Cell Adhesion | 1 | 2007 | 158 | 0.020 |
Why?
| Transforming Growth Factor beta1 | 1 | 2007 | 60 | 0.020 |
Why?
| Immunohistochemistry | 1 | 2010 | 978 | 0.020 |
Why?
| Estradiol | 1 | 2008 | 225 | 0.020 |
Why?
| Receptors, Bradykinin | 1 | 2006 | 2 | 0.020 |
Why?
| Drug Combinations | 1 | 2007 | 126 | 0.020 |
Why?
| rho-Associated Kinases | 1 | 2006 | 20 | 0.020 |
Why?
| Drug Synergism | 1 | 2006 | 151 | 0.020 |
Why?
| Viper Venoms | 1 | 2005 | 7 | 0.020 |
Why?
| Microsomes | 1 | 2006 | 35 | 0.020 |
Why?
| Enzyme Induction | 1 | 2006 | 79 | 0.020 |
Why?
| Electric Stimulation | 1 | 2006 | 118 | 0.020 |
Why?
| Receptor, Adenosine A1 | 1 | 2005 | 1 | 0.020 |
Why?
| Uridine Triphosphate | 1 | 2005 | 15 | 0.020 |
Why?
| Fibronectins | 1 | 2005 | 39 | 0.020 |
Why?
| Intracellular Membranes | 1 | 2005 | 25 | 0.020 |
Why?
| Gallic Acid | 1 | 2005 | 1 | 0.020 |
Why?
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 1 | 2005 | 1 | 0.020 |
Why?
| Inositol 1,4,5-Trisphosphate | 1 | 2005 | 10 | 0.020 |
Why?
| Clofibrate | 1 | 2005 | 7 | 0.020 |
Why?
| Potassium Chloride | 1 | 2005 | 20 | 0.020 |
Why?
| Diltiazem | 1 | 2005 | 10 | 0.020 |
Why?
| Enzyme Activation | 1 | 2006 | 275 | 0.020 |
Why?
| ortho-Aminobenzoates | 1 | 2005 | 7 | 0.020 |
Why?
| Reactive Oxygen Species | 1 | 2007 | 408 | 0.020 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 143 | 0.020 |
Why?
| Calibration | 1 | 2005 | 58 | 0.020 |
Why?
| Adenosine | 1 | 2005 | 70 | 0.020 |
Why?
| Calcium Channel Blockers | 1 | 2005 | 63 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2005 | 377 | 0.010 |
Why?
| Xanthines | 1 | 2003 | 8 | 0.010 |
Why?
| Chronic Disease | 1 | 2006 | 571 | 0.010 |
Why?
| Furosemide | 1 | 2003 | 10 | 0.010 |
Why?
| Diuretics | 1 | 2003 | 26 | 0.010 |
Why?
| Perfusion | 1 | 2003 | 48 | 0.010 |
Why?
| Mixed Function Oxygenases | 1 | 2003 | 25 | 0.010 |
Why?
| Severity of Illness Index | 1 | 2005 | 951 | 0.010 |
Why?
| Microvilli | 1 | 2002 | 6 | 0.010 |
Why?
| Fluoresceins | 1 | 2002 | 15 | 0.010 |
Why?
| Delayed-Action Preparations | 1 | 2002 | 51 | 0.010 |
Why?
| Dextrans | 1 | 2002 | 18 | 0.010 |
Why?
| Drug Implants | 1 | 2002 | 35 | 0.010 |
Why?
| Protein Isoforms | 1 | 2002 | 119 | 0.010 |
Why?
| Systole | 1 | 2002 | 71 | 0.010 |
Why?
| Reference Values | 1 | 2002 | 310 | 0.010 |
Why?
| Antibodies | 1 | 2002 | 154 | 0.010 |
Why?
| Diet | 1 | 2003 | 557 | 0.010 |
Why?
| Flow Cytometry | 1 | 2002 | 476 | 0.010 |
Why?
|
|
Imig's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|